784210-88-4|RGB-286638,developed by Agennix, also inhibits several CDKs in the low nanomolar IC50 range: CDK1 (IC50: 2 nM), CDK2 (IC50: 3 nM), CDK3 (IC50: 5 nM), CDK4 (IC50: 4 nM) and CDK9 (IC50: 1 nM). RGB-286638 has completed phase I clinical development for the treatment of multiple myeloma and solid tumors, but a planned phase I clinical trial for relapsed or refractory hematological malignancies was withdrawn in 2012 prior to enrollment. Moreover, Agennix announced on May 2013 its dissolution and that the liquidation should take place in 2014, therefore we have no clear vision for the future development of RGB-286638
Copyright © 2014-2015 Tubepharm. All Rights Reserved.
Tel：+86 021 5433 8626 Fax：+86 021 5433 8626*801 E-mail: firstname.lastname@example.org
All of our products, unless clearly indicated otherwise, are sold for research or manufacturing purposes only, are not for human, veterinary and household use.
The products under valid patent protection are not offered at this time. It is fully client's responsibility to comply with the rules, regulations and patent laws.